Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

GHENT, Belgium, December 14, 2023--Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

Related Keywords

Belgium ,Gretchen Schweitzer ,Tim Knotnerus ,Trophic Communications ,Agomab Therapeutics ,Single Ascending Dose ,Multiple Ascending Dose ,Chief Development Officer ,Idiopathic Pulmonary Fibrosis ,Fibrostenosing Crohn ,Idiopathic Pulmonary ,Transforming Growth Factor ,Hepatocyte Growth Factor ,Stephanie May ,Lung Transplant ,Lung Diseases ,Business Wire ,